Beijing Beilu Pharmaceutical
Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride … Read more
Beijing Beilu Pharmaceutical (300016) - Net Assets
Latest net assets as of September 2025: CN¥2.37 Billion CNY
Based on the latest financial reports, Beijing Beilu Pharmaceutical (300016) has net assets worth CN¥2.37 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.22 Billion) and total liabilities (CN¥852.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.37 Billion |
| % of Total Assets | 73.53% |
| Annual Growth Rate | 19.23% |
| 5-Year Change | -3.31% |
| 10-Year Change | 96.16% |
| Growth Volatility | 49.43 |
Beijing Beilu Pharmaceutical - Net Assets Trend (2005–2024)
This chart illustrates how Beijing Beilu Pharmaceutical's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Beijing Beilu Pharmaceutical (2005–2024)
The table below shows the annual net assets of Beijing Beilu Pharmaceutical from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.83 Billion | +2.42% |
| 2023-12-31 | CN¥1.79 Billion | -7.12% |
| 2022-12-31 | CN¥1.92 Billion | -7.74% |
| 2021-12-31 | CN¥2.08 Billion | +10.18% |
| 2020-12-31 | CN¥1.89 Billion | +30.44% |
| 2019-12-31 | CN¥1.45 Billion | +20.30% |
| 2018-12-31 | CN¥1.21 Billion | +12.77% |
| 2017-12-31 | CN¥1.07 Billion | +18.58% |
| 2016-12-31 | CN¥901.69 Million | -3.32% |
| 2015-12-31 | CN¥932.63 Million | +39.96% |
| 2014-12-31 | CN¥666.33 Million | +19.12% |
| 2013-12-31 | CN¥559.38 Million | +6.76% |
| 2012-12-31 | CN¥523.96 Million | +6.61% |
| 2011-12-31 | CN¥491.47 Million | +5.10% |
| 2010-12-31 | CN¥467.62 Million | +7.82% |
| 2009-12-31 | CN¥433.71 Million | +225.53% |
| 2008-12-31 | CN¥133.23 Million | +47.49% |
| 2007-12-31 | CN¥90.33 Million | +26.19% |
| 2006-12-31 | CN¥71.59 Million | +10.63% |
| 2005-12-31 | CN¥64.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Beijing Beilu Pharmaceutical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 4175.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥773.05 Million | 46.36% |
| Common Stock | CN¥491.95 Million | 29.50% |
| Other Comprehensive Income | CN¥273.93 Million | 16.43% |
| Other Components | CN¥128.67 Million | 7.72% |
| Total Equity | CN¥1.67 Billion | 100.00% |
Beijing Beilu Pharmaceutical Competitors by Market Cap
The table below lists competitors of Beijing Beilu Pharmaceutical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ardagh Metal Packaging SA
NYSE:AMBP
|
$605.72 Million |
|
Sturm Ruger & Company Inc
NYSE:RGR
|
$605.75 Million |
|
Guangdong Cellwise Microelectronics Co. Ltd.
SHG:688325
|
$605.77 Million |
|
Boozt AB (publ)
PINK:BZTAF
|
$605.80 Million |
|
Daewoong Pharma
KO:069620
|
$605.61 Million |
|
AP (Thailand) Public Company Limited
BK:AP-R
|
$605.57 Million |
|
Societe LDC SA
PA:LOUP
|
$605.29 Million |
|
Xizi Clean Energy Equipment Manufacturing Co Ltd
SHE:002534
|
$605.26 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Beijing Beilu Pharmaceutical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,650,617,396 to 1,667,588,937, a change of 16,971,541 (1.0%).
- Net income of 13,651,677 contributed positively to equity growth.
- Dividend payments of 20,899,201 reduced retained earnings.
- Other comprehensive income increased equity by 163,259,004.
- Other factors decreased equity by 139,039,939.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥13.65 Million | +0.82% |
| Dividends Paid | CN¥20.90 Million | -1.25% |
| Other Comprehensive Income | CN¥163.26 Million | +9.79% |
| Other Changes | CN¥-139.04 Million | -8.34% |
| Total Change | CN¥- | 1.03% |
Book Value vs Market Value Analysis
This analysis compares Beijing Beilu Pharmaceutical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.09x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 42.33x to 3.09x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | CN¥0.25 | CN¥10.46 | x |
| 2006-12-31 | CN¥0.27 | CN¥10.46 | x |
| 2007-12-31 | CN¥0.35 | CN¥10.46 | x |
| 2008-12-31 | CN¥0.43 | CN¥10.46 | x |
| 2009-12-31 | CN¥1.19 | CN¥10.46 | x |
| 2010-12-31 | CN¥1.02 | CN¥10.46 | x |
| 2011-12-31 | CN¥1.07 | CN¥10.46 | x |
| 2012-12-31 | CN¥1.16 | CN¥10.46 | x |
| 2013-12-31 | CN¥1.24 | CN¥10.46 | x |
| 2014-12-31 | CN¥1.34 | CN¥10.46 | x |
| 2015-12-31 | CN¥2.01 | CN¥10.46 | x |
| 2016-12-31 | CN¥1.84 | CN¥10.46 | x |
| 2017-12-31 | CN¥2.16 | CN¥10.46 | x |
| 2018-12-31 | CN¥2.45 | CN¥10.46 | x |
| 2019-12-31 | CN¥2.97 | CN¥10.46 | x |
| 2020-12-31 | CN¥3.59 | CN¥10.46 | x |
| 2021-12-31 | CN¥3.85 | CN¥10.46 | x |
| 2022-12-31 | CN¥3.61 | CN¥10.46 | x |
| 2023-12-31 | CN¥3.45 | CN¥10.46 | x |
| 2024-12-31 | CN¥3.39 | CN¥10.46 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Beijing Beilu Pharmaceutical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.39%
- • Asset Turnover: 0.33x
- • Equity Multiplier: 1.79x
- Recent ROE (0.82%) is below the historical average (10.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 14.27% | 10.89% | 0.78x | 1.68x | CN¥2.73 Million |
| 2006 | 17.27% | 9.78% | 1.00x | 1.77x | CN¥5.17 Million |
| 2007 | 30.70% | 11.92% | 1.64x | 1.57x | CN¥18.66 Million |
| 2008 | 19.60% | 14.70% | 1.11x | 1.20x | CN¥12.76 Million |
| 2009 | 8.04% | 16.08% | 0.48x | 1.04x | CN¥-8.50 Million |
| 2010 | 9.15% | 23.49% | 0.38x | 1.02x | CN¥-3.99 Million |
| 2011 | 9.00% | 22.48% | 0.37x | 1.07x | CN¥-4.94 Million |
| 2012 | 12.03% | 23.01% | 0.47x | 1.11x | CN¥10.64 Million |
| 2013 | 11.79% | 19.89% | 0.53x | 1.11x | CN¥10.03 Million |
| 2014 | 13.92% | 19.72% | 0.49x | 1.46x | CN¥24.45 Million |
| 2015 | 3.66% | 6.63% | 0.47x | 1.18x | CN¥-56.54 Million |
| 2016 | 1.82% | 3.28% | 0.52x | 1.06x | CN¥-73.79 Million |
| 2017 | 11.11% | 22.74% | 0.46x | 1.07x | CN¥11.89 Million |
| 2018 | 12.25% | 24.30% | 0.47x | 1.07x | CN¥27.18 Million |
| 2019 | 23.61% | 41.81% | 0.50x | 1.12x | CN¥197.39 Million |
| 2020 | 10.03% | 21.12% | 0.29x | 1.63x | CN¥511.44K |
| 2021 | 6.76% | 14.87% | 0.29x | 1.56x | CN¥-60.13 Million |
| 2022 | 0.64% | 1.47% | 0.27x | 1.59x | CN¥-166.35 Million |
| 2023 | -4.35% | -8.06% | 0.32x | 1.71x | CN¥-236.82 Million |
| 2024 | 0.82% | 1.39% | 0.33x | 1.79x | CN¥-153.11 Million |
Industry Comparison
This section compares Beijing Beilu Pharmaceutical's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Beijing Beilu Pharmaceutical (300016) | CN¥2.37 Billion | 14.27% | 0.36x | $605.65 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |